Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Observational

Follow-up Visit of High Risk Infants

NCT00009633 · tracked via the Priya Life Science Mexico tracker
Phase
Observational
Started
1993-04-01
Last updated
2026-07-01

Condition(s) studied

Infant, NewbornInfant, Low Birth WeightInfant, Small for Gestational AgeInfant, Premature

Investigational drug(s) / intervention(s)

No Intervention

No Intervention: No Intervention

Study summary

The NICHD Neonatal Research Network's Follow-Up study is a multi-center cohort in which surviving extremely low birth-weight infants born in participating network centers receive neurodevelopmental, neurosensory and functional assessments at 22-26 months corrected age (Infants born prior to July 1, 2012 were seen at 18-22 months corrected age). Data regarding pregnancy and neonatal outcome are collected prospectively. The goal is to identify potential maternal and neonatal risk factors that may affect infant neurodevelopment.

Eligibility

Sex
ALL
Min age
18 Months
Max age
26 Months
Healthy volunteers
No
* Infants inborn at NRN centers * \<27 weeks gestational age * Infants enrolled in one or more additional NICHD NRN Follow-up studies. For infants that do not meet the inclusion criteria above, inclusion and exclusion criteria are determined by the criteria for the additional trial(s). In these cases, infants that are larger than 1,000 grams and/or older than 27 weeks may be included in the FU Study. Note: These inclusion criteria were changed as of 1/1/2008. Prior to this date, infants with birth weights between 401 and 1500 grams who were admitted to NRN NICUs within 14 days of birth were included in the database.

Primary outcome measure(s)

  • To maintain a registry of baseline and outcome data for VLBW infants with data collected in a uniform manner — Longitudinal database currently funded through 3/31/2016

Trial sites (31)

FacilityCityRegionStatus
University of Alabama at Birmingham Birmingham Alabama Recruiting
University of California - Los Angeles Los Angeles California Recruiting
Stanford University Palo Alto California Recruiting
University of California at San Diego San Diego California Completed
Sharp Mary Birch Hospital for Women & Newborns San Diego California Not Yet Recruiting
Yale University New Haven Connecticut Completed
George Washington University Washington D.C. District of Columbia Completed
University of Miami Miami Florida Completed
Emory University Atlanta Georgia Recruiting
Northwestern Lurie Children's Hospital of Chicago Chicago Illinois Not Yet Recruiting
Indiana University Indianapolis Indiana Recruiting
University of Iowa Iowa City Iowa Recruiting
Tufts Medical Center Boston Massachusetts Completed
Harvard University Cambridge Massachusetts Completed
Wayne State University Detroit Michigan Recruiting
University of Mississippi Medical Center - Children's of Mississippi Jackson Mississippi Not Yet Recruiting
Children's Mercy Hospital Kansas City Missouri Recruiting
University of New Mexico Albuquerque New Mexico Recruiting
University of Rochester Rochester New York Active Not Recruiting
Wake Forest University Charlotte North Carolina Completed
RTI International Durham North Carolina Active Not Recruiting
Duke University Durham North Carolina Recruiting
Cincinnati Children's Medical Center Cincinnati Ohio Recruiting
Case Western Reserve University, Rainbow Babies and Children's Hospital Cleveland Ohio Recruiting
Research Institute at Nationwide Children's Hospital Columbus Ohio Active Not Recruiting
University of Pennsylvania Philadelphia Pennsylvania Recruiting
Brown University, Women & Infants Hospital of Rhode Island Providence Rhode Island Active Not Recruiting
University of Tennessee Memphis Tennessee Completed
University of Texas Southwestern Medical Center at Dallas Dallas Texas Recruiting
University of Texas Health Science Center at Houston Houston Texas Recruiting
University of Utah Salt Lake City Utah Recruiting

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT00009633 on ClinicalTrials.gov ↗ ← All trials in Mexico